Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ADAPT-MRD: ctDNA-guided adjuvant therapy after resection of pancreatic cancer

Randomized trial comparing ctDNA-guided adjuvant therapy with standard adjuvant therapy after radical resection of pancreatic cancer. ClinicalTrials.gov lists the study as recruiting, with a start date of June 1, 2025.

Ruijin Hospital